181 related articles for article (PubMed ID: 37460674)
21. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
22. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
[TBL] [Abstract][Full Text] [Related]
23. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
24. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
[TBL] [Abstract][Full Text] [Related]
26. Correlation Between
Santiago T; Tarek N; Boulos F; Hayes C; Jeha S; Raimondi S; Rodriguez-Galindo C
J Glob Oncol; 2019 Jul; 5():1-7. PubMed ID: 31365300
[TBL] [Abstract][Full Text] [Related]
27.
Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092
[TBL] [Abstract][Full Text] [Related]
28.
Bhardwaj N; Rohilla M; Trehan A; Bansal D; Kakkar N; Srinivasan R
J Clin Pathol; 2023 Sep; 76(9):599-605. PubMed ID: 35414524
[TBL] [Abstract][Full Text] [Related]
29. MYCN gene amplification in patients with neuroblastic tumors.
Estiar MA; Fazilaty H; Aslanabadi S; Seifi M; Varghaei P; Rezamand A
Cell Mol Biol (Noisy-le-grand); 2014 Sep; 60(3):23-8. PubMed ID: 25231001
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemistry for ATRX Can Miss ATRX Mutations: Lessons From Neuroblastoma.
Chami R; Marrano P; Teerapakpinyo C; Arnoldo A; Shago M; Shuangshoti S; Thorner PS
Am J Surg Pathol; 2019 Sep; 43(9):1203-1211. PubMed ID: 31290759
[TBL] [Abstract][Full Text] [Related]
31. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients.
Wang M; Zhou C; Cai R; Li Y; Gong L
Diagn Pathol; 2013 Jan; 8():5. PubMed ID: 23320395
[TBL] [Abstract][Full Text] [Related]
32. Regulation of MYCN expression in human neuroblastoma cells.
Jacobs JF; van Bokhoven H; van Leeuwen FN; Hulsbergen-van de Kaa CA; de Vries IJ; Adema GJ; Hoogerbrugge PM; de Brouwer AP
BMC Cancer; 2009 Jul; 9():239. PubMed ID: 19615087
[TBL] [Abstract][Full Text] [Related]
33. Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma.
Su Y; Wang L; Zhao Q; Yue Z; Zhao W; Wang X; Duan C; Jin M; Zhang D; Chen S; Yin J; Qiu L; Cheng X; Xu Z; Ma X
Mol Oncol; 2020 Nov; 14(11):2884-2893. PubMed ID: 32896084
[TBL] [Abstract][Full Text] [Related]
34. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
[TBL] [Abstract][Full Text] [Related]
35. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk
Wei JS; Kuznetsov IB; Zhang S; Song YK; Asgharzadeh S; Sindiri S; Wen X; Patidar R; Najaraj S; Walton A; Auvil JMG; Gerhard DS; Yuksel A; Catchpoole D; Hewitt SM; Sondel PM; Seeger R; Maris JM; Khan J
Clin Cancer Res; 2018 Nov; 24(22):5673-5684. PubMed ID: 29784674
[No Abstract] [Full Text] [Related]
36. [Prognostic significance of MYCN amplification in children neuroblastic tumors].
Niu H; Xu T; Wang F; Chen Z; Gao Q; Yi P; Xia J
Zhonghua Bing Li Xue Za Zhi; 2015 Feb; 44(2):111-7. PubMed ID: 25916642
[TBL] [Abstract][Full Text] [Related]
37. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
38. Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma.
Manohar CF; Salwen HR; Brodeur GM; Cohn SL
Genes Chromosomes Cancer; 1995 Nov; 14(3):196-203. PubMed ID: 8589036
[TBL] [Abstract][Full Text] [Related]
39. Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples.
Somasundaram DB; Aravindan S; Yu Z; Jayaraman M; Tran NTB; Li S; Herman TS; Aravindan N
BMC Cancer; 2019 Jan; 19(1):106. PubMed ID: 30691436
[TBL] [Abstract][Full Text] [Related]
40. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.
Ribatti D; Raffaghello L; Pastorino F; Nico B; Brignole C; Vacca A; Ponzoni M
Int J Cancer; 2002 Dec; 102(4):351-4. PubMed ID: 12402304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
